Aptamers evolved from live cells as effective molecular probes for cancer study

By D. Shangguan, Y. Li, Zhiwen Tang, Z. Cao, H. Chen, P. Mallikaratchy, K. Sefah, C. Yang, W. Tan. Proceedings of the National Academy of Sciences of the United States of America, 2006

1,316 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/3e5b27ea51d11a1043349608d447579a59ad4492

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Joon Won Park
2. Young-Eun Choi
3. Ju-Won Kwak

In Molecular Biology

1. Joon Won Park
2. Young-Eun Choi
3. Ju-Won Kwak

Citations in the corpus

• Nanomedicine in cancer therapy (2023, background): “231 Further investigations demonstrated that the aptamer sgc8 is speci fi cally bound to transmembrane receptor known as protein tyrosine kinase 7 (PTK7).”
• Nanotechnology for Early Cancer Detection (2010, methodology): “Blood 2007, 109, 5096-5103.”
• SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. (2007, neutral): “8–229 nmol/L Shangguan et al. (2006)”
• Cancer active targeting by nanoparticles: a comprehensive review of literature (2014, neutral): “2) (Shangguan et al. 2006).”
• Aptamers in the Therapeutics and Diagnostics Pipelines (2018, background): “Aptamers are single-stranded DNA or RNA oligonucleotides that bind with high affinity and high specificity to various targets ranging from various ions, small organic compounds to large proteins and live cells [1-8].”